US20050287630A1
(en)
*
|
1995-04-27 |
2005-12-29 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
EP1978033A3
(en)
*
|
1995-04-27 |
2008-12-24 |
Amgen Fremont Inc. |
Human antibodies derived from immunized xenomice
|
US20050241006A1
(en)
*
|
1995-04-27 |
2005-10-27 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US20020173629A1
(en)
*
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6235883B1
(en)
*
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6358508B1
(en)
*
|
1997-06-11 |
2002-03-19 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor TR9
|
US6417168B1
(en)
*
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
US7067144B2
(en)
*
|
1998-10-20 |
2006-06-27 |
Omeros Corporation |
Compositions and methods for systemic inhibition of cartilage degradation
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
CZ303703B6
(cs)
*
|
1998-12-23 |
2013-03-20 |
Pfizer Inc. |
Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
CA2363779A1
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
SK16522001A3
(sk)
*
|
1999-05-14 |
2002-10-08 |
Imclone Systems Incorporated |
Liečivo na inhibíciu rastu refraktérnych nádorov
|
CN100340575C
(zh)
|
1999-06-25 |
2007-10-03 |
杰南技术公司 |
人源化抗ErbB2抗体及其在制备药物中的应用
|
EP1792991A1
(en)
|
1999-08-24 |
2007-06-06 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
GB0002952D0
(en)
*
|
2000-02-09 |
2000-03-29 |
Pharma Mar Sa |
Process for producing kahalalide F compounds
|
KR101111103B1
(ko)
|
2000-02-10 |
2012-02-13 |
아보트 러보러터리즈 |
사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
|
CA2405701A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP1294949A4
(en)
|
2000-06-15 |
2004-08-25 |
Human Genome Sciences Inc |
HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
|
KR101155294B1
(ko)
|
2000-06-16 |
2013-03-07 |
캠브리지 안티바디 테크놀로지 리미티드 |
면역특이적으로 BLyS에 결합하는 항체
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
WO2002011677A2
(en)
*
|
2000-08-09 |
2002-02-14 |
Imclone Systems Incorporated |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
JP4434580B2
(ja)
|
2000-11-28 |
2010-03-17 |
メディミューン,エルエルシー |
予防及び治療のために抗rsv抗体を投与/処方する方法
|
ES2727425T3
(es)
|
2000-12-12 |
2019-10-16 |
Medimmune Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
JP2004531217A
(ja)
|
2001-01-05 |
2004-10-14 |
ファイザー・インク |
インスリン様成長因子i受容体に対する抗体
|
EP1366058B1
(en)
|
2001-02-09 |
2011-01-26 |
Human Genome Sciences, Inc. |
Human g-protein chemokine receptor (ccr5) hdgnr10
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
CA2444632A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
EP2335728A1
(en)
|
2001-05-11 |
2011-06-22 |
Ludwig Institute for Cancer Research Ltd. |
Specific binding proteins and uses thereof
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
CA2447114A1
(en)
|
2001-05-16 |
2002-11-21 |
Abgenix, Inc. |
Human antipneumococcal antibodies from non-human animals
|
US7595378B2
(en)
*
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
KR20090125840A
(ko)
*
|
2001-06-13 |
2009-12-07 |
젠맵 에이/에스 |
표피 성장 인자 수용체 (egfr)에 대한 인간 모노클로날 항체
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
US7491530B2
(en)
*
|
2001-12-18 |
2009-02-17 |
Whitehead Institute For Biomedical Research |
Fusion partner cells and uses thereof
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20080063639A1
(en)
*
|
2002-01-18 |
2008-03-13 |
Pierre Fabre Medicament |
Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
|
US7241444B2
(en)
*
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
US20080193445A1
(en)
*
|
2002-01-18 |
2008-08-14 |
Liliane Goetsch |
Novel anti-IGF-IR antibodies and uses thereof
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
JP2005521401A
(ja)
|
2002-03-27 |
2005-07-21 |
イミュネックス・コーポレーション |
ポリペプチド産生を増加させる方法
|
JP2005530490A
(ja)
|
2002-03-29 |
2005-10-13 |
シェーリング コーポレイション |
インターロイキン−5に対するヒトモノクローナル抗体および方法およびこれを含む組成物
|
US7371383B2
(en)
|
2002-04-12 |
2008-05-13 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
PL375064A1
(en)
*
|
2002-05-20 |
2005-11-14 |
Abgenix, Inc. |
Treatment of renal carcinoma using antibodies against the egfr
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US20040022792A1
(en)
*
|
2002-06-17 |
2004-02-05 |
Ralph Klinke |
Method of stabilizing proteins at low pH
|
WO2004000102A2
(en)
*
|
2002-06-19 |
2003-12-31 |
Abgenix, Inc. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
NZ537660A
(en)
|
2002-07-15 |
2008-12-24 |
Genentech Inc |
Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
|
CA2495251C
(en)
|
2002-08-14 |
2018-03-06 |
Macrogenics, Inc. |
Fc.gamma.riib-specific antibodies and methods of use thereof
|
CA2832136C
(en)
|
2002-09-27 |
2015-11-17 |
Xencor |
Optimized fc variants and methods for their generation
|
KR101388611B1
(ko)
|
2002-10-16 |
2014-04-23 |
퍼듀 퍼머 엘피 |
세포-연관된 ca 125/o772p에 결합하는 항체들 및 그것의 용도의 방법들
|
GB0304367D0
(en)
*
|
2003-02-26 |
2003-04-02 |
Pharma Mar Sau |
Methods for treating psoriasis
|
EP1565478B1
(en)
*
|
2002-11-12 |
2017-08-02 |
The Brigham And Women's Hospital, Inc. |
Polysaccharide vaccine for staphylococcal infections
|
US20040147428A1
(en)
*
|
2002-11-15 |
2004-07-29 |
Pluenneke John D. |
Methods of treatment using an inhibitor of epidermal growth factor receptor
|
AU2003300899A1
(en)
*
|
2002-12-12 |
2004-06-30 |
Oncotech, Inc. |
Genes related to sensitivity and resistance to chemotherapeutic drug treatment
|
US7276372B2
(en)
|
2002-12-20 |
2007-10-02 |
Pdl Biopharma, Inc. |
Antibodies against GPR64 and uses thereof
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
US20080014594A1
(en)
*
|
2003-01-31 |
2008-01-17 |
Kevin Hestir |
Lung-Expressed Polypeptides
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
ES2347959T3
(es)
|
2003-02-20 |
2010-11-26 |
Seattle Genetics, Inc. |
Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer.
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
HUE025347T2
(en)
|
2003-03-19 |
2016-02-29 |
Biogen Ma Inc |
NOGO receptor binding protein
|
KR20120035234A
(ko)
|
2003-04-11 |
2012-04-13 |
메디뮨 엘엘씨 |
재조합 il?9 항체 및 그의 용도
|
WO2004092220A1
(en)
*
|
2003-04-14 |
2004-10-28 |
Board Of Regents, The University Of Texas System |
Methods for ex vivo hybridoma-free production of polyclonal and monoclonal antibodies and generation of immortalized cell populations
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
EP2389953A1
(en)
|
2003-06-09 |
2011-11-30 |
Samuel Waksal |
Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
|
KR20160003332A
(ko)
*
|
2003-06-27 |
2016-01-08 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
|
EP1644408A1
(en)
|
2003-07-15 |
2006-04-12 |
Barros Research Institute |
Eimeria tenella antigen for immunotherapy of coccidiosis
|
CA2534661A1
(en)
|
2003-08-08 |
2005-02-17 |
Genenews Inc. |
Osteoarthritis biomarkers and uses thereof
|
GB0321066D0
(en)
*
|
2003-09-09 |
2003-10-08 |
Pharma Mar Sau |
New antitumoral compounds
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
NZ583292A
(en)
|
2003-11-06 |
2012-03-30 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
US7371381B2
(en)
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
US7674459B2
(en)
|
2003-12-23 |
2010-03-09 |
Genentech, Inc. |
Treatment of cancer with a novel anti-IL13 monoclonal antibody
|
JP2007537717A
(ja)
*
|
2004-01-07 |
2007-12-27 |
ブリストル−マイヤーズ スクイブ カンパニー |
上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
|
CA2552523C
(en)
|
2004-01-09 |
2019-11-26 |
Pfizer Inc. |
Monoclonal antibodies to mucosal addressin cell adhesion molecule(madcam)
|
ATE552851T1
(de)
|
2004-02-03 |
2012-04-15 |
Univ Michigan |
Zusammensetzungen zur behandlung von brust- und bauchspeicheldrüsenkrebs
|
BRPI0507026A
(pt)
|
2004-02-09 |
2007-04-17 |
Human Genome Sciences Inc |
proteìnas de fusão de albumina
|
TW200533339A
(en)
*
|
2004-03-16 |
2005-10-16 |
Bristol Myers Squibb Co |
Therapeutic synergy of anti-cancer compounds
|
DK1735348T3
(da)
*
|
2004-03-19 |
2012-07-16 |
Imclone Llc |
Humant anti-epidermalt vækstfaktorreceptorantistof
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
MXPA06011199A
(es)
|
2004-03-31 |
2007-04-16 |
Genentech Inc |
Anticuerpos anti-tgf-beta humanizados.
|
WO2005099756A2
(en)
|
2004-04-08 |
2005-10-27 |
Agus David B |
ErbB ANTAGONISTS FOR PAIN THERAPY
|
DK1745075T3
(da)
|
2004-04-21 |
2013-06-24 |
Brigham & Womens Hospital |
Poly-n-acetylglucosamin (pnag/dpnag)-bindende peptider og fremgangsmåder til anvendelse deraf
|
ES2552774T3
(es)
|
2004-06-01 |
2015-12-02 |
Icahn School Of Medicine At Mount Sinai |
Virus de la gripe porcina modificado por ingeniería genética y usos de los mismos
|
CN102973947A
(zh)
|
2004-06-01 |
2013-03-20 |
健泰科生物技术公司 |
抗体-药物偶联物和方法
|
EP1784427A2
(en)
|
2004-06-01 |
2007-05-16 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
ES2395094T3
(es)
|
2004-06-24 |
2013-02-08 |
Biogen Idec Ma Inc. |
Tratamiento de afecciones que implican la desmielinización
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
EP2322217A3
(en)
|
2004-07-16 |
2011-09-28 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
|
JP5060293B2
(ja)
|
2004-08-03 |
2012-10-31 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
神経機能におけるtaj
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
EA012799B1
(ru)
|
2004-08-16 |
2009-12-30 |
Кварк Фармасьютикалс, Инк. |
Терапевтические применения ингибиторов rtp801
|
CA2486285C
(en)
|
2004-08-30 |
2017-03-07 |
Viktor S. Goldmakher |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
WO2006034292A2
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
BRPI0516284A
(pt)
|
2004-09-23 |
2008-09-02 |
Genentech Inc |
anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
WO2006047639A2
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
US8802820B2
(en)
*
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
JP4652414B2
(ja)
|
2004-11-12 |
2011-03-16 |
ゼンコー・インコーポレイテッド |
FcRnとの変化した結合を有するFc変異体
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
EP2769990A3
(en)
|
2004-12-02 |
2015-02-25 |
Domantis Limited |
Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
PL1846030T3
(pl)
|
2005-01-21 |
2019-05-31 |
Genentech Inc |
Ustalone dawkowanie przeciwciał her
|
CN103497993A
(zh)
|
2005-02-07 |
2014-01-08 |
基因信息公司 |
轻度骨关节炎生物标志物及其用途
|
CA2597924C
(en)
|
2005-02-15 |
2018-10-02 |
Duke University |
Anti-cd19 antibodies and uses in oncology
|
US20090155247A1
(en)
*
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
NZ590431A
(en)
|
2005-02-23 |
2012-08-31 |
Genentech Inc |
Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
|
JP2008531730A
(ja)
|
2005-03-04 |
2008-08-14 |
キュアーディーエム、インク. |
I型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物
|
SI1865986T1
(sl)
|
2005-03-08 |
2016-05-31 |
Pfizer Products Inc. |
Sestavki protitelesa proti CTLA-4
|
US20060216288A1
(en)
*
|
2005-03-22 |
2006-09-28 |
Amgen Inc |
Combinations for the treatment of cancer
|
ES2707152T3
(es)
|
2005-04-15 |
2019-04-02 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
KR100680141B1
(ko)
*
|
2005-04-20 |
2007-02-07 |
주식회사 녹십자 |
항-egf 수용체 단일클론항체 및 이를 생산하는하이브리도마 세포주
|
KR20080011403A
(ko)
|
2005-04-25 |
2008-02-04 |
화이자 인크. |
미오스타틴에 대한 항체
|
KR100990027B1
(ko)
|
2005-04-26 |
2010-10-26 |
화이자 인코포레이티드 |
P-카드헤린 항체
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
EP2221316A1
(en)
|
2005-05-05 |
2010-08-25 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
EP1888649A2
(en)
*
|
2005-05-09 |
2008-02-20 |
GlycArt Biotechnology AG |
Antigen binding molecules having modified fc regions and altered binding to fc receptors
|
AR053272A1
(es)
|
2005-05-11 |
2007-04-25 |
Hoffmann La Roche |
Determinacion de responsivos a la quimioterapia
|
CA2609667C
(en)
|
2005-05-25 |
2011-02-22 |
Curedm, Inc. |
Human proislet peptide, derivatives and analogs thereof, and methods of using same
|
GB0510790D0
(en)
|
2005-05-26 |
2005-06-29 |
Syngenta Crop Protection Ag |
Anti-CD16 binding molecules
|
CA2613512A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
WO2007005955A2
(en)
|
2005-06-30 |
2007-01-11 |
Centocor, Inc. |
Anti-il-23 antibodies, compositions, methods and uses
|
PT1904104E
(pt)
|
2005-07-08 |
2013-11-21 |
Biogen Idec Inc |
Anticorpos sp35 e suas utilizações
|
US20070190047A1
(en)
*
|
2005-07-29 |
2007-08-16 |
Amgen, Inc. |
Formulations that inhibit protein aggregation
|
WO2007021841A2
(en)
|
2005-08-10 |
2007-02-22 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
EP2500353A3
(en)
|
2005-08-19 |
2012-10-10 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
KR20140053410A
(ko)
|
2005-08-19 |
2014-05-07 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
US7612181B2
(en)
*
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
WO2007025044A2
(en)
*
|
2005-08-24 |
2007-03-01 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
US7537762B2
(en)
|
2005-09-07 |
2009-05-26 |
Amgen Fremont, Inc. |
Human monoclonal antibodies to activin receptor-like kinase-1
|
US8906864B2
(en)
|
2005-09-30 |
2014-12-09 |
AbbVie Deutschland GmbH & Co. KG |
Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
|
EP1931709B1
(en)
|
2005-10-03 |
2016-12-07 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
EP2319941A3
(en)
|
2005-10-21 |
2011-08-17 |
GeneNews Inc. |
Method and apparatus for correlating levels of biomarker products with disease
|
MX2008005764A
(es)
|
2005-11-04 |
2008-11-18 |
Biogen Idec Inc |
Metodos para promover el crecimiento de neuritas y la supervivencia en neuronas dopaminergicas.
|
NZ594285A
(en)
|
2005-11-04 |
2013-02-22 |
Genentech Inc |
USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES
|
CA2628238A1
(en)
|
2005-11-07 |
2007-05-18 |
The Scripps Research Institute |
Compositions and methods for controlling tissue factor signaling specificity
|
ATE461220T1
(de)
|
2005-11-12 |
2010-04-15 |
Lilly Co Eli |
Anti-egfr-antikörper
|
KR20080090408A
(ko)
|
2005-11-30 |
2008-10-08 |
아보트 러보러터리즈 |
항-Aβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
|
KR101439828B1
(ko)
|
2005-11-30 |
2014-09-17 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
|
NZ569428A
(en)
|
2005-12-02 |
2012-11-30 |
Biogen Idec Inc |
Treatment of conditions involving demyelination with a Sp35 antagonist
|
HUE037464T2
(hu)
|
2005-12-02 |
2018-08-28 |
Icahn School Med Mount Sinai |
Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk
|
WO2007067959A2
(en)
|
2005-12-07 |
2007-06-14 |
Medarex, Inc. |
Ctla-4 antibody dosage escalation regimens
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
AR056857A1
(es)
*
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
NL2000439C2
(nl)
|
2006-01-20 |
2009-03-16 |
Quark Biotech |
Therapeutische toepassingen van inhibitoren van RTP801.
|
DK1981902T3
(en)
|
2006-01-27 |
2015-10-05 |
Biogen Ma Inc |
Nogo Receptor Antagonists
|
SG10201504662WA
(en)
|
2006-06-14 |
2015-07-30 |
Macrogenics Inc |
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
|
PL2029173T3
(pl)
|
2006-06-26 |
2017-04-28 |
Macrogenics, Inc. |
Przeciwciała swoiste dla FC RIIB i sposoby ich zastosowania
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
USRE47123E1
(en)
|
2006-07-18 |
2018-11-13 |
Sanofi |
EPHA2 receptor antagonist antibodies
|
AU2007281774A1
(en)
|
2006-08-04 |
2008-02-14 |
Astrazeneca Ab |
Human antibodies to ErbB 2
|
EP2292663B1
(en)
|
2006-08-28 |
2013-10-02 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistic human light-specific human monoclonal antibodies
|
RU2472807C2
(ru)
|
2006-09-08 |
2013-01-20 |
Эбботт Лэборетриз |
Интерлейкин-13-связывающие белки
|
CA2662236A1
(en)
|
2006-09-12 |
2008-03-20 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of cancer
|
TW200831129A
(en)
*
|
2006-10-06 |
2008-08-01 |
Amgen Inc |
Stable formulations
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
CA2665826A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
AU2007309616B2
(en)
*
|
2006-10-20 |
2011-10-06 |
Amgen Inc. |
Stable polypeptide formulations
|
WO2008064306A2
(en)
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
FR2909092B1
(fr)
*
|
2006-11-24 |
2012-10-19 |
Pf Medicament |
Nouveaux anticorps anti-proliferation
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP2687232A1
(en)
|
2006-12-06 |
2014-01-22 |
MedImmune, LLC |
Methods of treating systemic lupus erythematosus
|
AR064388A1
(es)
|
2006-12-18 |
2009-04-01 |
Genentech Inc |
Anticuerpos antagonistas anti- notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3
|
WO2008079976A2
(en)
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Dimeric high affinity egfr constructs and uses thereof
|
WO2008079973A2
(en)
*
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Egfr binding peptides and uses thereof
|
WO2008079982A2
(en)
*
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Liposome composition for targeting egfr receptor
|
CA2671585A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Novelix Therapeutics Gmbh |
Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof
|
EP3239175A1
(en)
|
2007-01-05 |
2017-11-01 |
University of Zurich |
Method of providing disease-specific binding molecules and targets
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
SI2068887T1
(sl)
|
2007-01-09 |
2014-06-30 |
Biogen Idec Ma Inc. |
SP35 protitelesa in njihova uporaba
|
WO2008088823A2
(en)
|
2007-01-16 |
2008-07-24 |
Abbott Laboratories |
Methods for treating psoriasis
|
CN104043123B
(zh)
|
2007-01-25 |
2019-08-13 |
达娜-法勃肿瘤研究所公司 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
KR20080074683A
(ko)
*
|
2007-02-09 |
2008-08-13 |
삼성전자주식회사 |
디지털 저작권 관리 방법 및 장치
|
WO2008101184A2
(en)
|
2007-02-16 |
2008-08-21 |
The Board Of Trustees Of Southern Illinois University |
Arl-1 specific antibodies
|
US8685666B2
(en)
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
US8895004B2
(en)
|
2007-02-27 |
2014-11-25 |
AbbVie Deutschland GmbH & Co. KG |
Method for the treatment of amyloidoses
|
KR101676622B1
(ko)
*
|
2007-03-01 |
2016-11-17 |
심포젠 에이/에스 |
재조합 항-표피 성장 인자 수용체 항체 조성물
|
MX2009008981A
(es)
|
2007-03-02 |
2009-09-02 |
Genentech Inc |
Prediccion de respuesta a un inhibidor her.
|
CA2680330A1
(en)
|
2007-03-13 |
2008-09-18 |
Alberto Bardelli |
K-ras and b-raf mutations and anti-egfr antibody therapy
|
TW200902553A
(en)
|
2007-03-13 |
2009-01-16 |
Amgen Inc |
K-ras mutations and anti-EGFr antibody therapy
|
CN101688229B
(zh)
|
2007-03-15 |
2013-06-12 |
路德维格癌症研究所 |
包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
KR101540823B1
(ko)
|
2007-03-30 |
2015-07-30 |
메디뮨 엘엘씨 |
항체 제제
|
PA8775101A1
(es)
|
2007-04-02 |
2008-11-19 |
Pfizer |
Anticuerpos anti-ige
|
PL2068927T3
(pl)
|
2007-05-14 |
2016-06-30 |
Medimmune Llc |
Sposoby redukcji poziomów eozynofilii
|
SI2171090T1
(sl)
|
2007-06-08 |
2013-07-31 |
Genentech, Inc. |
Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
|
US20100322939A1
(en)
*
|
2007-06-21 |
2010-12-23 |
Genmab A/S |
Novel methods for treating egfr-associated tumors
|
CN101821288A
(zh)
|
2007-06-21 |
2010-09-01 |
宏观基因有限公司 |
共价双抗体及其用途
|
CN101896503B
(zh)
|
2007-08-14 |
2018-05-22 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
CA3128656A1
(en)
|
2007-08-22 |
2009-02-26 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
KR101599704B1
(ko)
|
2007-08-29 |
2016-03-07 |
사노피 |
인간화된 항-cxcr5 항체, 이의 유도체 및 이들의 용도
|
BRPI0815308A2
(pt)
|
2007-08-30 |
2016-07-19 |
Curedm Inc |
peptídeo das pró-ilhotas de lagerhans, composição farmacûtica, método para estimular na neogêneses das ilhotas ou estimular a regeneração das ilhotas de langerhans e método para tratar uma patologia associada com a função pancreática defeituosa em um indivíduo
|
CA2698809C
(en)
|
2007-09-14 |
2023-10-17 |
Amgen Inc. |
Homogeneous antibody populations
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
US7985559B2
(en)
|
2007-10-19 |
2011-07-26 |
Amgen Inc. |
Methods of selecting epidermal growth factor receptor (EGFR) binding agents
|
US8663980B2
(en)
|
2007-10-26 |
2014-03-04 |
Janssen Biotech, Inc. |
Vectors, host cells, and methods of production and uses
|
ES2557352T3
(es)
|
2007-11-05 |
2016-01-25 |
Medimmune, Llc |
Métodos de tratamiento de la esclerodermia
|
JP5490714B2
(ja)
|
2007-11-28 |
2014-05-14 |
メディミューン,エルエルシー |
タンパク質製剤
|
ES2526433T3
(es)
|
2007-12-26 |
2015-01-12 |
Biotest Ag |
Inmunoconjugados dirigidos a CD138 y usos de los mismos
|
ES2543201T3
(es)
|
2007-12-26 |
2015-08-17 |
Biotest Ag |
Métodos y agentes que mejoran la dirección a las células tumorales que expresan CD138
|
CA2710680C
(en)
|
2007-12-26 |
2018-10-16 |
Vaccinex, Inc. |
Anti-c35 antibody combination therapies and methods
|
PL2808343T3
(pl)
|
2007-12-26 |
2019-11-29 |
Xencor Inc |
Warianty Fc ze zmienionym wiązaniem do FcRn
|
CA2710453C
(en)
|
2007-12-26 |
2019-07-02 |
Biotest Ag |
Agents targeting cd138 and uses thereof
|
AR069979A1
(es)
|
2007-12-26 |
2010-03-03 |
Biotest Ag |
Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
|
US8454960B2
(en)
*
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
US8557242B2
(en)
*
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US8557243B2
(en)
*
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
WO2009092011A1
(en)
|
2008-01-18 |
2009-07-23 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
AU2009209541A1
(en)
*
|
2008-01-30 |
2009-08-06 |
Pharma Mar, S.A. |
Improved antitumoral treatments
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
US20110059078A1
(en)
|
2008-02-08 |
2011-03-10 |
Medimmune, Llc |
Anti-ifnar1 antibodies with reduced fc ligand affinity
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
EP2262522A1
(en)
*
|
2008-03-07 |
2010-12-22 |
Pharma Mar, S.A. |
Improved antitumoral treatments
|
US8178092B2
(en)
|
2008-03-18 |
2012-05-15 |
Abbott Laboratories |
Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
|
WO2009118300A1
(en)
|
2008-03-25 |
2009-10-01 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
EP2274008B1
(en)
|
2008-03-27 |
2014-02-26 |
ZymoGenetics, Inc. |
Compositions and methods for inhibiting pdgfrbeta and vegf-a
|
CL2009000843A1
(es)
*
|
2008-04-11 |
2009-07-24 |
Galaxy Biotech Llc |
Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
|
CN102016026B
(zh)
|
2008-04-25 |
2014-07-02 |
东丽株式会社 |
含有来自丙型肝炎病毒的嵌合基因的核酸
|
MX2010011955A
(es)
|
2008-04-29 |
2011-01-21 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
AU2009242453B2
(en)
|
2008-05-02 |
2014-12-04 |
Seagen Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
AR071698A1
(es)
|
2008-05-09 |
2010-07-07 |
Abbott Gmbh & Co Kg |
Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
|
WO2009148896A2
(en)
|
2008-05-29 |
2009-12-10 |
Nuclea Biotechnologies, LLC |
Anti-phospho-akt antibodies
|
NZ589436A
(en)
*
|
2008-06-03 |
2012-12-21 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
MX2010013239A
(es)
*
|
2008-06-03 |
2011-02-24 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
CN102149825B
(zh)
|
2008-07-08 |
2015-07-22 |
Abbvie公司 |
前列腺素e2双重可变结构域免疫球蛋白及其用途
|
JP2011527579A
(ja)
|
2008-07-08 |
2011-11-04 |
アボット・ラボラトリーズ |
プロスタグランジンe2結合タンパク質およびこの使用
|
EP2315779A2
(en)
|
2008-07-09 |
2011-05-04 |
Biogen Idec MA Inc. |
Compositions comprising antibodies to lingo or fragments thereof
|
CA2731384C
(en)
*
|
2008-07-21 |
2015-03-10 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
|
WO2010017598A1
(en)
|
2008-08-14 |
2010-02-18 |
Arana Therapeutics Limited |
Anti-il-12/il-23 antibodies
|
RU2547595C2
(ru)
|
2008-08-18 |
2015-04-10 |
Пфайзер Инк |
Антитела против ccr2
|
KR101706255B1
(ko)
*
|
2008-08-29 |
2017-02-14 |
심포젠 에이/에스 |
재조합 항-표피 성장 인자 수용체 항체 조성물
|
ES2549877T3
(es)
|
2008-09-07 |
2015-11-02 |
Glyconex Inc. |
Anticuerpo antiglucoesfingolípido de tipo I extendido, derivados del mismo y utilización
|
CN110317272A
(zh)
|
2008-10-14 |
2019-10-11 |
霍夫曼-拉罗奇有限公司 |
免疫球蛋白变体及其用途
|
EP3351628B1
(en)
|
2008-10-24 |
2023-07-26 |
The Government of The United States of America as represented by The Secretary, Department of Health and Human Services |
Human ebola virus species and compositions and methods thereof
|
WO2010052288A1
(en)
|
2008-11-07 |
2010-05-14 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
EP2191843A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
|
EP2191841A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
EP2191842A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
WO2010065882A1
(en)
*
|
2008-12-04 |
2010-06-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
EP2376109B1
(en)
|
2008-12-19 |
2019-01-23 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
CN102341411A
(zh)
|
2008-12-31 |
2012-02-01 |
比奥根艾迪克Ma公司 |
抗-淋巴细胞毒素抗体
|
RU2636046C2
(ru)
|
2009-01-12 |
2017-11-17 |
Сайтомкс Терапьютикс, Инк |
Композиции модифицированных антител, способы их получения и применения
|
KR101245929B1
(ko)
|
2009-01-20 |
2013-03-22 |
호메이욘 에이치. 자데흐 |
항체 매개된 골질 재생
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP2396035A4
(en)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
|
EP2398494A4
(en)
|
2009-02-23 |
2015-10-28 |
Cytomx Therapeutics Inc |
Proproteins and their methods of use
|
JP5836807B2
(ja)
|
2009-03-05 |
2015-12-24 |
アッヴィ・インコーポレイテッド |
Il−17結合タンパク質
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
EP2408817B1
(en)
|
2009-03-20 |
2016-03-16 |
F.Hoffmann-La Roche Ag |
Bispecific anti-her antibodies
|
WO2010111180A1
(en)
|
2009-03-24 |
2010-09-30 |
Teva Biopharmaceuticals Usa, Inc. |
Humanized antibodies against light and uses thereof
|
US9051359B2
(en)
|
2009-03-30 |
2015-06-09 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccines and uses thereof
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
US20120135005A1
(en)
|
2009-04-16 |
2012-05-31 |
Harding Fiona A |
ANTI-TNF-a ANTIBODIES AND THEIR USES
|
MX2011013781A
(es)
|
2009-06-17 |
2012-05-29 |
Abbott Biotherapeutics Corp |
Anticuerpos anti-vegf y sus usos.
|
BRPI1015234A2
(pt)
|
2009-06-22 |
2018-02-20 |
Medimmune Llc |
regiões fc projetadas para conjugação sítio específica.
|
EP2461870B1
(en)
|
2009-07-22 |
2017-09-06 |
Biothera, Inc. |
Composition comprising beta-glucan and an egf-r antibody or an egf-r antagonist for use in the treatment of kras-mutated tumors
|
WO2011014504A1
(en)
|
2009-07-27 |
2011-02-03 |
Mount Sinai School Of Medicine Of New York University |
Recombinant influenza virus vectors and uses thereof
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
US8828406B2
(en)
|
2009-07-30 |
2014-09-09 |
Icahn School Of Medicine At Mount Sinai |
Influenza viruses and uses thereof
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
MX2012001882A
(es)
|
2009-08-13 |
2012-04-11 |
Crucell Holland Bv |
Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
|
CN102741288B
(zh)
|
2009-08-29 |
2015-08-19 |
Abbvie公司 |
治疗用dll4结合蛋白
|
PE20121530A1
(es)
|
2009-09-01 |
2012-12-22 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
ES2354922B1
(es)
|
2009-09-02 |
2012-02-07 |
Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron |
Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
UY32914A
(es)
|
2009-10-02 |
2011-04-29 |
Sanofi Aventis |
Anticuerpos que se usan específicamente al receptor epha2
|
ES2672121T3
(es)
|
2009-10-07 |
2018-06-12 |
Macrogenics, Inc. |
Polipéptidos que contienen región Fc que presentan una función efectora mejorada debido a alteraciones del grado de fucosilación, y métodos para su uso
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
JP2013507928A
(ja)
|
2009-10-15 |
2013-03-07 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリンおよびその使用
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US8658175B2
(en)
|
2009-10-28 |
2014-02-25 |
Abbvie Biotherapeutics Inc. |
Anti-EGFR antibodies and their uses
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
US20120220594A1
(en)
|
2009-10-30 |
2012-08-30 |
Bristol-Meyers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
TW201121568A
(en)
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
WO2011056073A2
(en)
|
2009-11-04 |
2011-05-12 |
Erasmus University Medical Center Rotterdam |
Novel compounds for modulating neovascularisation and methods of treatment using these compounds
|
KR20120103587A
(ko)
|
2009-11-12 |
2012-09-19 |
제넨테크, 인크. |
수상돌기 소극 밀도를 증진시키는 방법
|
ES2655737T3
(es)
|
2009-11-13 |
2018-02-21 |
Daiichi Sankyo Europe Gmbh |
Materiales y métodos para tratar o prevenir las enfermedades asociadas a HER-3
|
CN102770456B
(zh)
|
2009-12-04 |
2018-04-06 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体、抗体类似物、组合物和方法
|
CN102656190A
(zh)
|
2009-12-08 |
2012-09-05 |
雅培股份有限两合公司 |
用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
|
WO2011084496A1
(en)
|
2009-12-16 |
2011-07-14 |
Abbott Biotherapeutics Corp. |
Anti-her2 antibodies and their uses
|
AR079984A1
(es)
|
2010-01-12 |
2012-03-07 |
Hoffmann La Roche |
Compuestos heterociclicos triciclicos, composiciones y su uso en el tratamiento de enfermedades mediadas por la inhibicion de jak1
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
US20110189178A1
(en)
*
|
2010-02-04 |
2011-08-04 |
Xencor, Inc. |
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
|
BR112012020102A2
(pt)
|
2010-02-10 |
2016-11-29 |
Immunogen Inc |
anticorpos cd20 e usos dos mesmos.
|
US9556249B2
(en)
|
2010-02-18 |
2017-01-31 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
AU2011223919B2
(en)
|
2010-03-02 |
2015-03-19 |
Abbvie Inc. |
Therapeutic DLL4 binding proteins
|
AU2011222867B2
(en)
|
2010-03-04 |
2014-03-06 |
Annika Algars |
Method for selecting patients for treatment with an EGFR inhibitor
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
US20130096104A1
(en)
|
2010-03-17 |
2013-04-18 |
Genentech, Inc. |
Imidazopyridine compounds, compositions and methods of use
|
RU2012145183A
(ru)
|
2010-03-29 |
2014-05-10 |
Займворкс, Инк. |
Антитела с повышенной или пониженной эффекторной функцией
|
EP3900740A1
(en)
|
2010-03-30 |
2021-10-27 |
Icahn School of Medicine at Mount Sinai |
Influenza virus vaccines and uses thereof
|
EP2371369A1
(en)
|
2010-04-01 |
2011-10-05 |
Institut Gustave Roussy (IGR) |
EGFR inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer
|
WO2011130377A2
(en)
|
2010-04-15 |
2011-10-20 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
EP3670534A3
(en)
*
|
2010-04-15 |
2020-09-09 |
Amgen Inc. |
Human fgf receptor and beta-klotho binding proteins
|
BR112012026470A2
(pt)
|
2010-04-16 |
2016-08-09 |
Genentech Inc |
método para prever a sensibilidade de crescimento de células tumorais e para tratar um tumor em um paciente
|
WO2011131611A1
(en)
|
2010-04-19 |
2011-10-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
KR101848225B1
(ko)
|
2010-05-14 |
2018-04-12 |
애브비 인코포레이티드 |
Il-1 결합 단백질
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011156617A2
(en)
|
2010-06-09 |
2011-12-15 |
Aveo Pharmaceuticals, Inc. |
Anti-egfr antibodies
|
EP2580239A1
(en)
|
2010-06-10 |
2013-04-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
JP2013530981A
(ja)
|
2010-06-25 |
2013-08-01 |
アストン ユニバーシティ |
脂質動員特性を有する糖タンパク質およびその治療的使用
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CN103097412B
(zh)
|
2010-07-09 |
2016-08-10 |
克鲁塞尔荷兰公司 |
抗人呼吸道合胞病毒(rsv)抗体以及使用方法
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
EP2601216B1
(en)
|
2010-08-02 |
2018-01-03 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
WO2012018790A2
(en)
|
2010-08-03 |
2012-02-09 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
SG187198A1
(en)
|
2010-08-05 |
2013-03-28 |
Amgen Inc |
Dipeptides to enhance yield and viability from cell cultures
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
CN103298833B
(zh)
|
2010-08-14 |
2015-12-16 |
Abbvie公司 |
β淀粉样蛋白结合蛋白
|
EP2606067B1
(en)
|
2010-08-19 |
2018-02-21 |
Zoetis Belgium S.A. |
Anti-ngf antibodies and their use
|
WO2012024659A2
(en)
|
2010-08-20 |
2012-02-23 |
Massachusetts Institute Of Technology |
Antibody-based constructs directed against tyrosine kinase receptors
|
CN103260639A
(zh)
|
2010-08-26 |
2013-08-21 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
JP2013537966A
(ja)
|
2010-08-31 |
2013-10-07 |
ジェネンテック, インコーポレイテッド |
バイオマーカー及び治療の方法
|
US20130171159A1
(en)
|
2010-09-10 |
2013-07-04 |
Brian Arthur Hemmings |
Phosphorylated twist1 and metastasis
|
CN103209695A
(zh)
|
2010-09-15 |
2013-07-17 |
弗·哈夫曼-拉罗切有限公司 |
氮杂苯并噻唑化合物、组合物及应用方法
|
CN104531812A
(zh)
|
2010-10-01 |
2015-04-22 |
现代治疗公司 |
设计核酸及其使用方法
|
EP3581206A1
(en)
|
2010-10-22 |
2019-12-18 |
Seattle Genetics, Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the p13k-akt mtor pathway
|
KR20140008308A
(ko)
|
2010-10-29 |
2014-01-21 |
이뮤노젠 아이엔씨 |
신규한 egfr-결합 분자 및 이의 면역컨쥬게이트
|
EP2632947A4
(en)
|
2010-10-29 |
2015-03-18 |
Immunogen Inc |
NON-ANTAGONIST MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF
|
WO2012065161A2
(en)
|
2010-11-12 |
2012-05-18 |
Scott & White Healthcare |
Antibodies to tumor endothelial marker 8
|
US20140093506A1
(en)
|
2010-11-15 |
2014-04-03 |
Marc Buehler |
Anti-fungal-agents
|
WO2012068487A1
(en)
|
2010-11-18 |
2012-05-24 |
Synta Pharmaceuticals Corp. |
Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
|
BR112013011520A2
(pt)
|
2010-11-19 |
2019-09-24 |
Hoffmann La Roche |
pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
AU2011361720B2
(en)
|
2010-12-21 |
2017-04-27 |
Abbvie Inc. |
IL-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
RU2013138177A
(ru)
|
2011-01-24 |
2015-03-10 |
Йм Биосайнсис Инк. |
Антитела, действующие селективно на клетки с повышенной плотностью мишени рецептор эпидермального фактора роста (egfr)
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
PL3235508T3
(pl)
|
2011-03-16 |
2021-07-12 |
Sanofi |
Kompozycje zawierające białko podobne do przeciwciała z podwójnym regionem v
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
SG194111A1
(en)
*
|
2011-04-07 |
2013-11-29 |
Amgen Inc |
Novel egfr binding proteins
|
SI2699293T1
(sl)
|
2011-04-20 |
2019-05-31 |
Amgen Inc. |
Avtoinjekcijski aparat
|
WO2012145493A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
US9133493B2
(en)
|
2011-04-21 |
2015-09-15 |
Amgen Inc. |
Method for culturing mammalian cells to improve recombinant protein production
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
WO2012162068A2
(en)
|
2011-05-21 |
2012-11-29 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
AU2012258637B2
(en)
|
2011-05-24 |
2017-07-20 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
WO2012168259A1
(en)
|
2011-06-06 |
2012-12-13 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
SI2718320T1
(en)
|
2011-06-10 |
2018-06-29 |
Medimmune Limited |
Molecules that bind anti-Pseudomonas psl and their use
|
JP2014527397A
(ja)
|
2011-06-20 |
2014-10-16 |
トラスラショナル、キャンサー、ドラッグス、ファーマ、ソシエダッド、リミターダTraslational Cancer Drugs Pharma, S.L. |
癌患者の化学療法に対する臨床応答を予測する方法
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
CA2838695C
(en)
|
2011-07-01 |
2017-02-14 |
Amgen Inc. |
Mammalian cell culture
|
WO2019071023A1
(en)
|
2017-10-04 |
2019-04-11 |
Yale University |
COMPOSITIONS AND METHODS FOR MAKING POLYPEPTIDES CONTAINING SELENOCYSTEINE
|
WO2013009868A1
(en)
|
2011-07-11 |
2013-01-17 |
Yale University |
Compositions and methods for making selenocysteine containing polypeptides
|
CA2841970A1
(en)
|
2011-07-13 |
2013-01-17 |
Abbvie Inc. |
Methods and compositions for treating asthma using anti-il-13 antibodies
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
KR20140047160A
(ko)
|
2011-08-12 |
2014-04-21 |
에프. 호프만-라 로슈 아게 |
인다졸 화합물, 조성물 및 사용 방법
|
AU2012296613B2
(en)
|
2011-08-15 |
2016-05-12 |
Amplimmune, Inc. |
Anti-B7-H4 antibodies and their uses
|
CA2842375A1
(en)
|
2011-08-17 |
2013-02-21 |
Erica Jackson |
Neuregulin antibodies and uses thereof
|
AU2012300279A1
(en)
|
2011-08-26 |
2014-04-03 |
Merrimack Pharmaceuticals, Inc. |
Tandem Fc bispecific antibodies
|
CA2840637A1
(en)
|
2011-09-02 |
2013-03-07 |
Amgen Inc. |
Pharmaceutical product and method of analysing light exposure of a pharmaceutical product
|
CA2848061C
(en)
|
2011-09-09 |
2019-10-22 |
Amgen Inc. |
Use of human papillomavirus status in establishing use of an agent that binds egfr in the treatment of cancer
|
CA2848074A1
(en)
|
2011-09-09 |
2013-03-14 |
Medimmune Limited |
Anti-siglec-15 antibodies and uses thereof
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
CA2845409A1
(en)
|
2011-09-20 |
2013-03-28 |
Yingjie Lai |
Imidazopyridine compounds, compositions and methods of use
|
EA201490659A1
(ru)
|
2011-09-20 |
2014-11-28 |
Маунт Синай Скул Оф Медсин |
Вакцины против вируса гриппа и их применения
|
ES2911677T3
(es)
|
2011-10-03 |
2022-05-20 |
Modernatx Inc |
Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
EP3611187A1
(en)
|
2011-10-10 |
2020-02-19 |
Xencor, Inc. |
A method for purifying antibodies
|
WO2013056069A1
(en)
|
2011-10-13 |
2013-04-18 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
RU2014120981A
(ru)
|
2011-10-24 |
2015-12-10 |
Эббви Инк. |
Иммунные связывающие агенты против склеростина
|
IN2014CN03936A
(el)
|
2011-10-24 |
2015-09-04 |
Abbvie Inc |
|
WO2013063419A2
(en)
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
AU2012332588B2
(en)
|
2011-11-01 |
2017-09-07 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
JP2014533247A
(ja)
|
2011-11-01 |
2014-12-11 |
バイオノミクス インコーポレイテッド |
抗体および癌を治療する方法
|
EP2773664A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
WO2013067060A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
ES2861435T3
(es)
|
2011-11-03 |
2021-10-06 |
Univ Pennsylvania |
Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas
|
US20140294732A1
(en)
|
2011-11-08 |
2014-10-02 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Early diagnostic of neurodegenerative diseases
|
WO2013070821A1
(en)
|
2011-11-08 |
2013-05-16 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
BR112014011115A2
(pt)
|
2011-11-08 |
2017-06-13 |
Pfizer |
métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf
|
CA2855746A1
(en)
|
2011-11-16 |
2013-05-23 |
John Stephen HILL |
Methods of treating epidermal growth factor deletion mutant viii related disorders
|
MX2014006087A
(es)
|
2011-11-21 |
2014-08-01 |
Immunogen Inc |
Metodo de tratamiento de tumores que son resistentes a terapias contra el receptor del factor de crecimiento epidermico (egfr) con agentes citotoxicos conjugados con anticuerpos dirigidos contra el receptor del factor de crecimiento epidermico.
|
CA2857114A1
(en)
|
2011-11-30 |
2013-06-06 |
Genentech, Inc. |
Erbb3 mutations in cancer
|
CA2858133A1
(en)
|
2011-12-08 |
2013-06-13 |
Biotest Ag |
Uses of immunoconjugates targeting cd138
|
US10118958B2
(en)
|
2011-12-14 |
2018-11-06 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
JP6336397B2
(ja)
|
2011-12-14 |
2018-06-06 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
鉄関連障害を診断および治療するための組成物および方法
|
AR089231A1
(es)
|
2011-12-15 |
2014-08-06 |
Amgen Inc |
Metodo de floculacion
|
RS63244B1
(sr)
|
2011-12-16 |
2022-06-30 |
Modernatx Inc |
Kompozicije modifikovane mrna
|
CN103172741B
(zh)
*
|
2011-12-20 |
2018-04-27 |
智翔(上海)医药科技有限公司 |
全人源抗egfr抗体
|
ES2721882T3
(es)
|
2011-12-23 |
2019-08-06 |
Pfizer |
Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
|
BR112014015851A2
(pt)
|
2011-12-30 |
2019-09-24 |
Abbvie Inc |
proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
|
WO2013102825A1
(en)
|
2012-01-02 |
2013-07-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
EP2804948B1
(en)
|
2012-01-20 |
2020-04-15 |
The Government of The Hong Kong Special Administrative Region of The People's Republic of China |
A novel paramyxovirus and uses thereof
|
JP6271441B2
(ja)
|
2012-01-27 |
2018-01-31 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
神経突起変性に関連する疾患を診断および治療するための組成物および方法
|
JP6335796B2
(ja)
*
|
2012-02-08 |
2018-06-06 |
アイジーエム バイオサイエンシズ インク.Igm Biosciences Inc. |
Cdim結合タンパク質及びその使用
|
CN104254778A
(zh)
|
2012-02-10 |
2014-12-31 |
西雅图遗传学公司 |
Cd30+癌症的检测和治疗
|
EP2814842B1
(en)
|
2012-02-15 |
2018-08-22 |
Novo Nordisk A/S |
Antibodies that bind peptidoglycan recognition protein 1
|
ES2640268T3
(es)
|
2012-02-15 |
2017-11-02 |
Novo Nordisk A/S |
Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1)
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
CA2865082A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
US20150266961A1
(en)
|
2012-03-29 |
2015-09-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute |
Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US20140010861A1
(en)
|
2012-04-02 |
2014-01-09 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
EP2836514A4
(en)
|
2012-04-13 |
2015-12-30 |
Childrens Medical Center |
TIKI INHIBITORS
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9980942B2
(en)
|
2012-05-02 |
2018-05-29 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
WO2013166290A1
(en)
|
2012-05-04 |
2013-11-07 |
Abbvie Biotherapeutics Inc. |
P21 biomarker assay
|
CA2873623C
(en)
|
2012-05-14 |
2021-11-09 |
Biogen Idec Ma Inc. |
Lingo-2 antagonists for treatment of conditions involving motor neurons
|
WO2013172951A1
(en)
|
2012-05-15 |
2013-11-21 |
Morphotek, Inc. |
Methods for treatment of gastric cancer
|
CN104918956A
(zh)
|
2012-05-17 |
2015-09-16 |
索伦托治疗有限公司 |
与egfr结合的抗原结合蛋白
|
US10233503B2
(en)
|
2012-05-24 |
2019-03-19 |
Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) |
Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis
|
WO2013177386A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Biotherapeutics Inc. |
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
CA2875783C
(en)
|
2012-06-06 |
2018-12-11 |
Zoetis Llc |
Caninized anti-ngf antibodies and methods thereof
|
EP2859017B1
(en)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
US20150218238A1
(en)
|
2012-06-29 |
2015-08-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Treating diseases by modulating a specific isoform of mkl1
|
US20150184154A1
(en)
|
2012-07-05 |
2015-07-02 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
New treatment for neurodegenerative diseases
|
US20150224190A1
(en)
|
2012-07-06 |
2015-08-13 |
Mohamed Bentires-Alj |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
|
US9670276B2
(en)
|
2012-07-12 |
2017-06-06 |
Abbvie Inc. |
IL-1 binding proteins
|
SG11201408787PA
(en)
|
2012-07-13 |
2015-01-29 |
Univ Pennsylvania |
Enhancing activity of car t cells by co-introducing a bispecific antibody
|
PT2882440T
(pt)
|
2012-08-07 |
2019-04-23 |
Array Biopharma Inc |
Combinações farmacêuticas compreendendo um inibidor de braf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa
|
SG11201501464TA
(en)
|
2012-08-31 |
2015-03-30 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
CA2883272A1
(en)
|
2012-09-02 |
2014-03-06 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
NO2760138T3
(el)
|
2012-10-01 |
2018-08-04 |
|
|
US9365641B2
(en)
|
2012-10-01 |
2016-06-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
WO2014055771A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
JP5993093B2
(ja)
|
2012-10-12 |
2016-09-14 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン類およびその複合体
|
AU2013334493B2
(en)
|
2012-10-26 |
2018-11-29 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
AU2013337644A1
(en)
|
2012-11-01 |
2015-05-07 |
Abbvie Inc. |
Stable Dual Variable Domain Immunoglobulin protein formulations
|
KR20210111353A
(ko)
|
2012-11-01 |
2021-09-10 |
애브비 인코포레이티드 |
항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
LT2922554T
(lt)
|
2012-11-26 |
2022-06-27 |
Modernatx, Inc. |
Terminaliai modifikuota rnr
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
UA118255C2
(uk)
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
CN108641002A
(zh)
|
2012-12-18 |
2018-10-12 |
西奈山伊坎医学院 |
流感病毒疫苗及其用途
|
EP2934575A2
(en)
|
2012-12-19 |
2015-10-28 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
CN104968679B
(zh)
|
2012-12-21 |
2019-04-16 |
艾普利穆恩公司 |
抗h7cr抗体
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
WO2014109858A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
CA2897987A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
US9834610B2
(en)
|
2013-01-31 |
2017-12-05 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector T cells
|
WO2014129895A1
(en)
|
2013-02-19 |
2014-08-28 |
Stichting Vu-Vumc |
Means and method for increasing the sensitivity of cancers for radiotherapy
|
BR112015018418A2
(pt)
|
2013-02-22 |
2017-07-18 |
Hoffmann La Roche |
métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
|
KR20150143458A
(ko)
|
2013-03-06 |
2015-12-23 |
메리맥 파마슈티컬즈, 인크. |
항-C-MET 탠덤 Fc 이중특이적 항체
|
MX2015011428A
(es)
|
2013-03-06 |
2016-02-03 |
Genentech Inc |
Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
|
EP2830651A4
(en)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
|
EP2970307B1
(en)
|
2013-03-13 |
2020-03-11 |
Genentech, Inc. |
Pyrazolo compounds and uses thereof
|
US20160022813A1
(en)
|
2013-03-13 |
2016-01-28 |
Sanofi |
Compositions comprising anti-cd38 antibodies and carfilzomib
|
NZ712035A
(en)
|
2013-03-13 |
2019-06-28 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
JP2016512032A
(ja)
|
2013-03-14 |
2016-04-25 |
アボツト・モレキユラー・インコーポレイテツド |
結腸直腸腺腫を評価するための材料および方法
|
US9194873B2
(en)
|
2013-03-14 |
2015-11-24 |
Abbott Laboratories |
HCV antigen-antibody combination assay and methods and compositions for use therein
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
JP2016512241A
(ja)
|
2013-03-14 |
2016-04-25 |
アボット・ラボラトリーズAbbott Laboratories |
改良された抗体検出のためのhcvns3組換え抗原およびこの突然変異体
|
TWI832345B
(zh)
|
2013-03-14 |
2024-02-11 |
美商安美基公司 |
用於增加重組蛋白質之甘露糖含量之方法
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
WO2014159960A1
(en)
|
2013-03-14 |
2014-10-02 |
Icahn School Of Medicine At Mount Sinai |
Antibodies against influenza virus hemagglutinin and uses thereof
|
EP3395423B1
(en)
|
2013-03-14 |
2023-09-20 |
Amgen Inc. |
Removal of leaked affinity purification ligand
|
CN113549148A
(zh)
|
2013-03-14 |
2021-10-26 |
雅培制药有限公司 |
Hcv核心脂质结合结构域单克隆抗体
|
KR20150127216A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
암의 치료 및 암 약물 내성의 예방 방법
|
KR20150127203A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법
|
SG11201507563SA
(en)
|
2013-03-14 |
2015-10-29 |
Parkash Gill |
Cancer treatment using antibodies that bind cell surface grp78
|
AU2014228772B2
(en)
|
2013-03-15 |
2019-02-28 |
Memorial Sloan Kettering Cancer Center |
High affinity anti-GD2 antibodies
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
EP2970489A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Biotechnology Ltd |
Anti-cd25 antibodies and their uses
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
CN105377892A
(zh)
|
2013-03-15 |
2016-03-02 |
艾伯维生物技术有限公司 |
抗cd25抗体及其用途
|
EP2968541A4
(en)
|
2013-03-15 |
2017-02-08 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
MX2015013166A
(es)
|
2013-03-15 |
2015-12-11 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
EP2968760B1
(en)
|
2013-03-15 |
2024-01-03 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
TWI639453B
(zh)
|
2013-03-15 |
2018-11-01 |
美商安美基公司 |
用於注射器之匣盒
|
JP6449229B2
(ja)
|
2013-03-15 |
2019-01-09 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Fc変異体
|
AU2014232416B2
(en)
|
2013-03-15 |
2017-09-28 |
Xencor, Inc. |
Modulation of T Cells with Bispecific Antibodies and FC Fusions
|
CA2905123A1
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
WO2014166029A1
(zh)
*
|
2013-04-07 |
2014-10-16 |
永卓博济(上海)生物医药技术有限公司 |
针对表皮生长因子受体的抗体
|
US20160030384A1
(en)
|
2013-04-09 |
2016-02-04 |
Boston Biomedical, Inc. |
2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
|
EP4032540A1
(en)
|
2013-04-19 |
2022-07-27 |
Cytune Pharma |
Cytokine derived treatment with reduced vascular leak syndrome
|
TWI679019B
(zh)
|
2013-04-29 |
2019-12-11 |
法商賽諾菲公司 |
抗il-4/抗il-13之雙特異性抗體調配物
|
JP2016521283A
(ja)
|
2013-05-06 |
2016-07-21 |
スカラー ロック インコーポレイテッドScholar Rock,Inc. |
成長因子モジュレーションのための組成物および方法
|
CN103290018B
(zh)
*
|
2013-05-07 |
2015-07-29 |
南方医科大学 |
一种与人表皮生长因子受体iii型突变体特异性结合的核酸适配子及其应用
|
CA2913312A1
(en)
|
2013-05-24 |
2014-11-27 |
Medimmune, Llc |
Anti-b7-h5 antibodies and their uses
|
US9481901B2
(en)
|
2013-05-30 |
2016-11-01 |
Amgen Inc. |
Methods for increasing mannose content of recombinant proteins
|
ES2891755T3
(es)
|
2013-06-06 |
2022-01-31 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
JP6581572B2
(ja)
|
2013-06-07 |
2019-09-25 |
デューク ユニバーシティ |
補体因子h阻害薬
|
MX2015017035A
(es)
|
2013-06-13 |
2016-04-25 |
Fast Forward Pharmaceuticals B V |
Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis.
|
US9499628B2
(en)
|
2013-06-14 |
2016-11-22 |
Children's Hospital Medical Center |
Method of boosting the immune response in neonates
|
US20170319709A1
(en)
|
2013-07-05 |
2017-11-09 |
Formation Biologics Inc. |
Egfr antibody conjugates
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
ES2761587T3
(es)
|
2013-08-07 |
2020-05-20 |
Friedrich Miescher Institute For Biomedical Res |
Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
MX2016002794A
(es)
|
2013-09-05 |
2016-09-13 |
Genentech Inc |
Compuestos antiproliferativos.
|
EP3041863A4
(en)
|
2013-09-05 |
2017-08-16 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
KR102435648B1
(ko)
|
2013-09-11 |
2022-08-25 |
이글 바이오로직스 인코퍼레이티드 |
점도저하제를 함유하는 액체 단백질 제형
|
EA201600252A1
(ru)
|
2013-09-12 |
2017-05-31 |
Галозим, Инк. |
Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
WO2015049325A1
(en)
|
2013-10-03 |
2015-04-09 |
F. Hoffmann-La Roche Ag |
Therapeutic inhibitors of cdk8 and uses thereof
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
JP6677638B2
(ja)
|
2013-10-18 |
2020-04-08 |
ジェネンテック, インコーポレイテッド |
抗rspo2及び/又はrspo3抗体及びそれらの使用
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
CA3120508A1
(en)
|
2013-10-28 |
2015-05-07 |
Dots Technology Corp. |
Allergen detection
|
CA2929077C
(en)
|
2013-10-31 |
2024-05-28 |
Amgen Inc. |
Use of monensin to regulate glycosylation of recombinant proteins
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
JP2017500307A
(ja)
|
2013-12-12 |
2017-01-05 |
ノバルティス アーゲー |
がんの処置のためのトラメチニブ、パニツムマブおよびダブラフェニブの組合せ
|
US9944694B2
(en)
|
2013-12-13 |
2018-04-17 |
Rijksuniversiteit Groningen |
Antibodies against Staphylococcus aureus and uses therof
|
EP3083692B1
(en)
|
2013-12-17 |
2020-02-19 |
F.Hoffmann-La Roche Ag |
Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
ES2920677T3
(es)
|
2013-12-24 |
2022-08-08 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-VISTA
|
EP2893939A1
(en)
|
2014-01-10 |
2015-07-15 |
Netris Pharma |
Anti-netrin-1 antibody
|
WO2015105609A1
(en)
|
2014-01-13 |
2015-07-16 |
Amgen Inc. |
Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
|
IL282517B
(en)
|
2014-01-29 |
2022-07-01 |
Amgen Inc |
Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
US10106829B2
(en)
|
2014-01-29 |
2018-10-23 |
Amgen Inc. |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
EP2915569A1
(en)
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
CN107002119A
(zh)
|
2014-03-24 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
|
BR112016022385A2
(pt)
|
2014-03-28 |
2018-06-19 |
Xencor, Inc |
anticorpos específicos que se ligam a cd38 e cd3
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
KR20160145624A
(ko)
|
2014-03-31 |
2016-12-20 |
제넨테크, 인크. |
항-ox40 항체 및 사용 방법
|
MX2016012873A
(es)
|
2014-04-04 |
2017-03-07 |
Bionomics Inc |
Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
|
JP6792454B2
(ja)
|
2014-04-25 |
2020-11-25 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
アルファ−フェトプロテイン(afp)を操作するための方法
|
EP3888690A3
(en)
|
2014-05-16 |
2021-10-20 |
MedImmune, LLC |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
EP3467501B1
(en)
|
2014-05-16 |
2020-11-04 |
Amgen Inc. |
Assay for detecting th1 and th2 cell populations
|
EP3498295A1
(en)
|
2014-05-28 |
2019-06-19 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
HUE042277T2
(hu)
|
2014-06-04 |
2019-06-28 |
Amgen Inc |
Eljárások fehérjék begyûjtésére emlõssejttenyészetekbõl
|
US20170137824A1
(en)
|
2014-06-13 |
2017-05-18 |
Indranil BANERJEE |
New treatment against influenza virus
|
JP5924795B2
(ja)
|
2014-06-13 |
2016-05-25 |
テンボロン オイ |
複合体
|
WO2015198202A1
(en)
|
2014-06-23 |
2015-12-30 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
EP3164129A1
(en)
|
2014-07-01 |
2017-05-10 |
Friedrich Miescher Institute for Biomedical Research |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
PE20170192A1
(es)
|
2014-07-17 |
2017-03-16 |
Novo Nordisk As |
Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad
|
WO2018140026A1
(en)
|
2017-01-27 |
2018-08-02 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
MA39070A1
(fr)
|
2014-07-31 |
2017-11-30 |
Sanofi Sa |
Anticorps anti-cd38 spécifiques pour le traitement de cancers humains
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
US20160058884A1
(en)
|
2014-09-02 |
2016-03-03 |
Immunogen, Inc. |
Methods for formulating antibody drug conjugate compositions
|
JP6814730B2
(ja)
|
2014-09-05 |
2021-01-20 |
ジェネンテック, インコーポレイテッド |
治療用化合物およびその使用
|
WO2016037644A1
(en)
|
2014-09-10 |
2016-03-17 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2016044694A1
(en)
|
2014-09-19 |
2016-03-24 |
Genentech, Inc. |
Use of cbp/ep300 and bet inhibitors for treatment of cancer
|
US20170298360A1
(en)
|
2014-09-24 |
2017-10-19 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
SG11201702614SA
(en)
|
2014-10-01 |
2017-04-27 |
Eagle Biolog Inc |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
EP3204379B1
(en)
|
2014-10-10 |
2019-03-06 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
WO2016059600A1
(en)
|
2014-10-17 |
2016-04-21 |
Novartis Ag |
Combination of ceritinib with an egfr inhibitor
|
CN107073116A
(zh)
|
2014-10-23 |
2017-08-18 |
依奈特制药公司 |
使用抗nkg2a试剂治疗癌症
|
CA2964953A1
(en)
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in cart cells and uses thereof
|
EP3212668B1
(en)
|
2014-10-31 |
2020-10-14 |
AbbVie Biotherapeutics Inc. |
Anti-cs1 antibodies and antibody drug conjugates
|
ES2910227T3
(es)
|
2014-10-31 |
2022-05-12 |
Univ Pennsylvania |
Composición y métodos para la estimulación y expansión de células T
|
AU2015343339A1
(en)
|
2014-11-03 |
2017-06-15 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment
|
WO2016073378A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
RU2017119428A
(ru)
|
2014-11-06 |
2018-12-06 |
Дженентек, Инк. |
Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
|
JP6639497B2
(ja)
|
2014-11-10 |
2020-02-05 |
ジェネンテック, インコーポレイテッド |
ブロモドメインインヒビターおよびその使用
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
FI3218005T3
(fi)
|
2014-11-12 |
2023-03-31 |
Seagen Inc |
Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
|
EP3221360A1
(en)
|
2014-11-17 |
2017-09-27 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
ES2962593T3
(es)
|
2014-11-19 |
2024-03-20 |
Amgen Inc |
Cuantificación de resto glucano en glucoproteínas recombinantes
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
TN2017000223A1
(en)
|
2014-11-26 |
2018-10-19 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
EA037065B1
(ru)
|
2014-11-26 |
2021-02-01 |
Ксенкор, Инк. |
Гетеродимерные антитела, связывающие cd3 и cd38
|
JP6771464B2
(ja)
|
2014-11-27 |
2020-10-21 |
ジェネンテック, インコーポレイテッド |
Cbpおよび/またはep300インヒビターとしての、4,5,6,7−テトラヒドロ−1h−ピラゾロ[4,3−c]ピリジン−3−アミン化合物
|
PL3227454T3
(pl)
|
2014-12-01 |
2020-07-27 |
Amgen Inc. |
Sposób manipulowania poziomem zawartości glikanów w glikoproteinie
|
AU2015360609A1
(en)
|
2014-12-09 |
2017-06-29 |
Abbvie Inc. |
Antibody drug conjugates with cell permeable Bcl-xL inhibitors
|
MX2017007629A
(es)
|
2014-12-09 |
2018-05-17 |
Abbvie Inc |
Compuestos inhibidores de bcl-xl que tienen una baja permeabilidad en las celulas y conjugados de anticuerpo-farmaco que los incluyen.
|
JP6864953B2
(ja)
|
2014-12-09 |
2021-04-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Axlに対するヒトモノクローナル抗体
|
PL3800202T3
(pl)
|
2014-12-11 |
2023-06-12 |
Pierre Fabre Medicament |
Przeciwciała przeciwko c10orf54 i ich zastosowania
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
EP3233897B1
(en)
|
2014-12-19 |
2021-02-17 |
Universite de Nantes |
Anti il-34 antibodies
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
EP3789039A1
(en)
|
2014-12-22 |
2021-03-10 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
AU2015369624A1
(en)
|
2014-12-23 |
2017-06-08 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
CN107208138A
(zh)
|
2014-12-30 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
用于癌症预后和治疗的方法和组合物
|
MX2017009038A
(es)
|
2015-01-08 |
2017-10-25 |
Biogen Ma Inc |
Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
|
EP3242872B1
(en)
|
2015-01-09 |
2019-07-03 |
Genentech, Inc. |
(piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
|
EP3242874B1
(en)
|
2015-01-09 |
2018-10-31 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
WO2016112251A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
AU2016206682B2
(en)
|
2015-01-14 |
2021-11-11 |
The Brigham And Women's Hospital, Inc. |
Treatment of cancer with anti-LAP monoclonal antibodies
|
CA2974699A1
(en)
|
2015-01-23 |
2016-07-28 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccination regimens
|
EP3250571B1
(en)
|
2015-01-29 |
2022-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
CN107438593B
(zh)
|
2015-01-30 |
2020-10-30 |
基因泰克公司 |
治疗化合物及其用途
|
EP4223873A3
(en)
|
2015-01-31 |
2023-09-06 |
The Trustees of the University of Pennsylvania |
Compositions and methods for t cell delivery of therapeutic molecules
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
EP3265123B1
(en)
|
2015-03-03 |
2022-10-26 |
Kymab Limited |
Antibodies, uses & methods
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
SG11201706659WA
(en)
|
2015-03-06 |
2017-09-28 |
Csl Behring Recombinant Facility Ag |
Modified von willebrand factor having improved half-life
|
IL296062A
(en)
|
2015-03-17 |
2022-10-01 |
Memorial Sloan Kettering Cancer Center |
Antibodies against muc16 and their uses
|
CN107709364A
(zh)
|
2015-04-07 |
2018-02-16 |
豪夫迈·罗氏有限公司 |
具有激动剂活性的抗原结合复合体及使用方法
|
KR20180015650A
(ko)
|
2015-05-07 |
2018-02-13 |
아게누스 인코포레이티드 |
항-ox40 항체 및 이의 사용 방법
|
SI3294770T1
(sl)
|
2015-05-12 |
2021-01-29 |
F. Hoffmann-La Roche Ag |
Terapevtski in diagnostični postopki za raka
|
WO2016187068A1
(en)
|
2015-05-15 |
2016-11-24 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
KR102661078B1
(ko)
|
2015-05-29 |
2024-05-23 |
애브비 인코포레이티드 |
항-cd40 항체 및 그의 용도
|
MA53355A
(fr)
|
2015-05-29 |
2022-03-16 |
Agenus Inc |
Anticorps anti-ctla-4 et leurs procédés d'utilisation
|
MX2017014736A
(es)
|
2015-05-29 |
2018-03-23 |
Genentech Inc |
Metodos terapeuticos y diagnosticos para cancer.
|
AU2016271475A1
(en)
|
2015-06-03 |
2017-12-21 |
Boston Biomedical, Inc. |
Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
|
MX2017015937A
(es)
|
2015-06-08 |
2018-12-11 |
Genentech Inc |
Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
|
WO2016200836A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
KR20180018538A
(ko)
|
2015-06-17 |
2018-02-21 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
|
DK3313882T3
(da)
|
2015-06-24 |
2020-05-11 |
Janssen Pharmaceutica Nv |
Anti-VISTA antistoffer og fragmenter
|
PL3341376T3
(pl)
|
2015-08-26 |
2021-08-02 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Skondensowane związki tricykliczne jako inhibitory kinaz białkowych
|
IL307276A
(en)
|
2015-08-28 |
2023-11-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
PE20181322A1
(es)
|
2015-09-01 |
2018-08-14 |
Agenus Inc |
Anticuerpo anti-pd1 y sus metodos de uso
|
MX2018003633A
(es)
|
2015-09-25 |
2018-08-01 |
Genentech Inc |
Anticuerpos anti-tigit y metodos de uso.
|
WO2017072669A1
(en)
|
2015-10-28 |
2017-05-04 |
Friedrich Miescher Institute For Biomedical Research |
Tenascin-w and biliary tract cancers
|
AR106543A1
(es)
|
2015-11-02 |
2018-01-24 |
Netris Pharma |
Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético
|
JP2019500011A
(ja)
|
2015-11-03 |
2019-01-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用
|
EP3373969A4
(en)
|
2015-11-12 |
2019-08-14 |
Siamab Therapeutics, Inc. |
GLYCANINTERAGING COMPOUNDS AND METHOD OF USE
|
JP2019501139A
(ja)
|
2015-11-25 |
2019-01-17 |
イミュノジェン・インコーポレーテッド |
医薬製剤及びその使用
|
AU2016365117A1
(en)
|
2015-11-30 |
2018-05-31 |
Abbvie Biotherapeutics Inc. |
Anti-huLRRC15 antibody drug conjugates and methods for their use
|
US10188660B2
(en)
|
2015-11-30 |
2019-01-29 |
Abbvie Inc. |
Anti-huLRRC15 antibody drug conjugates and methods for their use
|
US11253590B2
(en)
|
2015-12-02 |
2022-02-22 |
Stsciences, Inc. |
Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
|
EP3909983A1
(en)
|
2015-12-02 |
2021-11-17 |
STCube & Co. Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
CA3007030A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
HRP20220227T1
(hr)
|
2015-12-16 |
2022-04-29 |
Genentech, Inc. |
Postupak priprave tricikličnih spojeva inhibitora p13k i postupci upotrebe navedenih spojeva u liječenju raka
|
EP3184544A1
(en)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein v inhibitors for use as coagulants
|
KR102197478B1
(ko)
|
2015-12-31 |
2021-01-04 |
프로가스트린 에 캔서스 에스.에이 알.엘. |
식도암을 검출 및 치료하기 위한 조성물 및 방법
|
EA037015B1
(ru)
|
2015-12-31 |
2021-01-27 |
Прогастрин Э Кансер С.А Р.Л. |
Применение и способ для профилактики или лечения рака яичников с использованием композиции, содержащей прогастринсвязывающее антитело
|
CN108700586A
(zh)
|
2015-12-31 |
2018-10-23 |
Syncerus有限责任公司 |
用于评估癌症发生的风险的组合物和方法
|
US20190011449A1
(en)
|
2015-12-31 |
2019-01-10 |
Progastrine Et Cancers S.À R.L. |
Compositions and methods for detecting and treating gastric cancer
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
CA3014013A1
(en)
|
2016-02-12 |
2017-08-17 |
Janssen Pharmaceutica Nv |
Anti-vista (b7h5) antibodies
|
CN109196121B
(zh)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
US11319383B2
(en)
|
2016-03-14 |
2022-05-03 |
Universitetet | Oslo |
Engineered immunoglobulins with altered FcRn binding
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
SG11201808041UA
(en)
|
2016-03-17 |
2018-10-30 |
Numab Innovation Ag |
ANTI-TNFa-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
|
RS61374B1
(sr)
|
2016-03-17 |
2021-02-26 |
Tillotts Pharma Ag |
Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
|
KR102449711B1
(ko)
|
2016-03-17 |
2022-09-30 |
누맙 이노베이션 아게 |
항-TNFα-항체 및 이의 기능성 단편
|
PL3219727T3
(pl)
|
2016-03-17 |
2021-05-17 |
Tillotts Pharma Ag |
Przeciwciała anty-TNF alfa i ich funkcjonalne fragmenty
|
JP7049311B2
(ja)
|
2016-03-17 |
2022-04-06 |
ヌマブ イノヴェイション アーゲー |
抗TNFα抗体およびそれらの機能的断片
|
KR20220004226A
(ko)
|
2016-03-22 |
2022-01-11 |
바이오노믹스 리미티드 |
항-lgr5 단클론성 항체의 투여
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
WO2017172771A2
(en)
|
2016-03-29 |
2017-10-05 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
EP3865511A1
(en)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3 antibodies and methods of use
|
AU2017248766A1
(en)
|
2016-04-15 |
2018-11-01 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
JP2019518426A
(ja)
|
2016-04-15 |
2019-07-04 |
ジェネンテック, インコーポレイテッド |
がんの診断及び治療方法
|
WO2017181111A2
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
WO2017194568A1
(en)
|
2016-05-11 |
2017-11-16 |
Sanofi |
Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
|
HUE050398T2
(hu)
|
2016-05-17 |
2020-12-28 |
Abbvie Biotherapeutics Inc |
Anti-cMet-antitest-gyógyszer konjugátumok és eljárások alkalmazásukra
|
CN115028617A
(zh)
|
2016-05-24 |
2022-09-09 |
基因泰克公司 |
Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
|
US11649291B2
(en)
|
2016-05-24 |
2023-05-16 |
Insmed Incorporated |
Antibodies and methods of making same
|
CN109476663B
(zh)
|
2016-05-24 |
2021-11-09 |
基因泰克公司 |
用于治疗癌症的吡唑并吡啶衍生物
|
US10875921B2
(en)
|
2016-05-27 |
2020-12-29 |
Abbvie Biotherapeutics Inc. |
Anti-4-1BB antibodies and their uses
|
US10519243B2
(en)
|
2016-05-27 |
2019-12-31 |
Abbvie Biotherapeutics Inc. |
Anti-CD40 antibodies
|
MX2018014387A
(es)
|
2016-05-27 |
2019-03-14 |
Agenus Inc |
Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
|
WO2017210586A1
(en)
|
2016-06-03 |
2017-12-07 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
|
CN109312407A
(zh)
|
2016-06-08 |
2019-02-05 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
TWI762487B
(zh)
|
2016-06-08 |
2022-05-01 |
美商艾伯維有限公司 |
抗-b7-h3抗體及抗體藥物結合物
|
CN113773387B
(zh)
|
2016-06-13 |
2024-06-21 |
天境生物科技(上海)有限公司 |
Pd-l1抗体及其用途
|
CA3026151A1
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
WO2017218698A1
(en)
|
2016-06-15 |
2017-12-21 |
Sutro Biopharma, Inc. |
Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
|
US11266734B2
(en)
|
2016-06-15 |
2022-03-08 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus hemagglutinin proteins and uses thereof
|
JP7021127B2
(ja)
|
2016-06-28 |
2022-02-16 |
ゼンコア インコーポレイテッド |
ソマトスタチン受容体2に結合するヘテロ二量体抗体
|
EP3481864A1
(en)
|
2016-07-08 |
2019-05-15 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
US11046776B2
(en)
|
2016-08-05 |
2021-06-29 |
Genentech, Inc. |
Multivalent and multiepitopic antibodies having agonistic activity and methods of use
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
PL3512547T3
(pl)
|
2016-09-14 |
2021-03-08 |
Abbvie Biotherapeutics Inc. |
Przeciwciała anty-pd-1
|
WO2018050111A1
(en)
|
2016-09-19 |
2018-03-22 |
I-Mab |
Anti-gm-csf antibodies and uses thereof
|
EP4360714A2
(en)
|
2016-09-21 |
2024-05-01 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
US11390675B2
(en)
|
2016-09-21 |
2022-07-19 |
Nextcure, Inc. |
Antibodies for Siglec-15 and methods of use thereof
|
MX2019003703A
(es)
|
2016-09-30 |
2020-08-13 |
Janssen Biotech Inc |
Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
|
EP3519825A1
(en)
|
2016-10-03 |
2019-08-07 |
Abbott Laboratories |
Improved methods of assessing gfap status in patient samples
|
CN110418851A
(zh)
|
2016-10-06 |
2019-11-05 |
基因泰克公司 |
癌症的治疗和诊断方法
|
US10844119B2
(en)
|
2016-10-11 |
2020-11-24 |
Agenus Inc. |
Anti-LAG-3 antibodies and methods of use thereof
|
US20200023072A1
(en)
|
2016-10-11 |
2020-01-23 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
AU2017342560B2
(en)
|
2016-10-14 |
2022-03-17 |
Xencor, Inc. |
IL15/IL15Ralpha heterodimeric Fc-fusion proteins
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック, インコーポレイテッド |
抗mic抗体及び使用方法
|
CN110300600A
(zh)
|
2016-11-02 |
2019-10-01 |
伊缪诺金公司 |
利用抗体-药物缀合物和parp抑制剂的组合治疗
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
US11332521B2
(en)
|
2016-11-07 |
2022-05-17 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
MA46861A
(fr)
|
2016-11-16 |
2019-09-25 |
Janssen Biotech Inc |
Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
CA3045306A1
(en)
|
2016-11-29 |
2018-06-07 |
Boston Biomedical, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
WO2018106862A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
JP7106538B2
(ja)
|
2016-12-07 |
2022-07-26 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
PL3504242T3
(pl)
|
2016-12-15 |
2020-11-16 |
Abbvie Biotherapeutics Inc. |
Przeciwciała anty-ox40 i ich zastosowania
|
CN110291105B
(zh)
|
2017-01-05 |
2024-03-01 |
奈特里斯药物公司 |
导蛋白-1干扰药物和免疫检查点抑制剂药物的组合治疗
|
WO2018133837A1
(en)
|
2017-01-20 |
2018-07-26 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anti-pd-1 antibodies and uses thereof
|
CN112279918A
(zh)
|
2017-01-24 |
2021-01-29 |
天境生物科技(上海)有限公司 |
Cd73抗体及其用途
|
MX2019008989A
(es)
|
2017-01-30 |
2019-10-09 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa.
|
AU2017398101A1
(en)
|
2017-02-07 |
2019-08-01 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
|
JP7256127B2
(ja)
|
2017-03-01 |
2023-04-11 |
ジェネンテック, インコーポレイテッド |
がんのための診断及び治療方法
|
JP2020510671A
(ja)
|
2017-03-03 |
2020-04-09 |
シアトル ジェネティックス, インコーポレイテッド |
グリカン相互作用化合物および使用の方法
|
US20200131518A1
(en)
|
2017-03-14 |
2020-04-30 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
TWI808963B
(zh)
|
2017-03-22 |
2023-07-21 |
法商賽諾菲公司 |
使用人類化抗cxcr5抗體治療狼瘡
|
WO2018175942A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
EA201992316A1
(ru)
|
2017-03-30 |
2020-03-05 |
Эсс-Прогастрин Са |
Композиции и способы для диагностики рака предстательной железы
|
AU2018242157B2
(en)
|
2017-03-30 |
2023-02-09 |
Progastrine et Cancers S.à.r.l. |
Compositions and methods for treating lung cancer
|
CA3058652A1
(en)
|
2017-04-07 |
2018-10-11 |
Icahn School Of Medicine At Mount Sinai |
Anti-influenza b virus neuraminidase antibodies and uses thereof
|
AU2018253176B2
(en)
|
2017-04-13 |
2023-02-02 |
Agenus Inc. |
Anti-CD137 antibodies and methods of use thereof
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
CN110546513A
(zh)
|
2017-04-15 |
2019-12-06 |
雅培实验室 |
使用早期生物标记物帮助超急性诊断和确定人类受试者中的创伤性脑损伤的方法
|
AU2018255938A1
(en)
|
2017-04-21 |
2019-10-31 |
Staten Biotechnology B.V. |
Anti-ApoC3 antibodies and methods of use thereof
|
US20230140818A1
(en)
|
2017-04-27 |
2023-05-04 |
The University Of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
AU2018256845B2
(en)
|
2017-04-28 |
2024-03-14 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
TW202402800A
(zh)
|
2017-05-01 |
2024-01-16 |
美商艾吉納斯公司 |
抗tigit抗體類和使用彼等之方法
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
WO2018211517A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
US10646464B2
(en)
|
2017-05-17 |
2020-05-12 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
CN110651190A
(zh)
|
2017-05-25 |
2020-01-03 |
雅培实验室 |
用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
|
CN110720041B
(zh)
|
2017-05-30 |
2024-04-26 |
雅培实验室 |
用心肌肌钙蛋白i和早期生物标记物帮助诊断和评价人受试者中轻度创伤性脑损伤的方法
|
JP7369038B2
(ja)
|
2017-05-31 |
2023-10-25 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1に免疫特異的に結合する抗体及び分子並びにその治療的使用
|
AU2018277545A1
(en)
|
2017-05-31 |
2019-12-19 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
|
WO2018226671A1
(en)
|
2017-06-06 |
2018-12-13 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
CN111032694B
(zh)
|
2017-07-14 |
2024-03-08 |
辉瑞大药厂 |
针对madcam的抗体
|
CA3069469A1
(en)
|
2017-07-21 |
2019-01-24 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
US20210032364A1
(en)
|
2017-07-27 |
2021-02-04 |
Nomocan Pharmaceuticals Llc |
Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
|
WO2020159504A1
(en)
|
2019-01-30 |
2020-08-06 |
Nomocan Pharmaceuticals Llc |
Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
|
KR20200037366A
(ko)
|
2017-08-11 |
2020-04-08 |
제넨테크, 인크. |
항-cd8 항체 및 이의 용도
|
JP2020532991A
(ja)
|
2017-09-07 |
2020-11-19 |
オーガスタ ユニバーシティ リサーチ インスティテュート,インコーポレーテッド |
プログラム細胞死タンパク質1に対する抗体
|
JP2020532982A
(ja)
|
2017-09-08 |
2020-11-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんの診断及び治療方法
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
CA3019207A1
(en)
|
2017-09-28 |
2019-03-28 |
The Governing Council Of The University Of Toronto |
Methods and compositions for inhibiting mutant egfr signaling
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
EP3710001A4
(en)
|
2017-10-27 |
2021-07-14 |
University Of Virginia Patent Foundation |
COMPOUNDS AND PROCEDURES FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
|
WO2019089594A1
(en)
|
2017-10-31 |
2019-05-09 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and cytarabine
|
EP3704148A1
(en)
|
2017-10-31 |
2020-09-09 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
CN111213059B
(zh)
|
2017-11-06 |
2024-01-09 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
CN112272563A
(zh)
|
2017-11-08 |
2021-01-26 |
Xencor股份有限公司 |
使用新颖抗pd-1序列的双特异性和单特异性抗体
|
AU2018368338A1
(en)
|
2017-11-16 |
2020-04-09 |
Amgen Inc. |
Autoinjector with stall and end point detection
|
CN111727075B
(zh)
|
2017-11-27 |
2024-04-05 |
普渡制药公司 |
靶向人组织因子的人源化抗体
|
SG11202005296SA
(en)
|
2017-12-05 |
2020-07-29 |
Progastrine Et Cancers S A R L |
Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
|
JP7344801B2
(ja)
|
2017-12-09 |
2023-09-14 |
アボット・ラボラトリーズ |
グリア原線維性酸性タンパク質(gfap)及び/又はユビキチンカルボキシ末端ヒドロラーゼl1(uch-l1)を使用する、整形外科損傷を負っており、軽度外傷性脳損傷(tbi)などの頭部への損傷を負ったか又は負った可能性がある対象についての診断及び査定の一助となるための方法
|
JP7379165B2
(ja)
|
2017-12-09 |
2023-11-14 |
アボット・ラボラトリーズ |
Gfapとuch-l1との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
WO2019145537A1
(en)
|
2018-01-26 |
2019-08-01 |
Ecs-Progastrin Sa |
Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
|
EP3759141A1
(en)
|
2018-02-26 |
2021-01-06 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
SG11202008271QA
(en)
|
2018-02-27 |
2020-09-29 |
Ecs Progastrin Sa |
Progastrin as a biomarker for immunotherapy
|
WO2019169229A1
(en)
|
2018-03-01 |
2019-09-06 |
Nextcure, Inc. |
Klrg1 binding compositions and methods of use thereof
|
EP3762015A4
(en)
|
2018-03-05 |
2022-04-27 |
Janssen Biotech, Inc. |
METHODS OF TREATING CROHN'S DISEASE WITH SPECIFIC ANTI-IL23 ANTIBODY
|
CA3093772C
(en)
|
2018-03-12 |
2024-04-16 |
Zoetis Services Llc |
Anti-ngf antibodies and methods thereof
|
SG11202009216YA
(en)
|
2018-03-26 |
2020-10-29 |
Amgen Inc |
Total afucosylated glycoforms of antibodies produced in cell culture
|
MX2020010204A
(es)
|
2018-04-02 |
2021-01-29 |
Bristol Myers Squibb Co |
Anticuerpos anti-trem-1 y usos de los mismos.
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
CN112004558A
(zh)
|
2018-04-12 |
2020-11-27 |
米迪亚制药有限责任公司 |
Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RA Fc融合タンパク質およびTIM−3抗原結合ドメインを含む、TIM−3標的化ヘテロ二量体融合タンパク質
|
WO2019204665A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
EP3784274A1
(en)
|
2018-04-27 |
2021-03-03 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
CA3098805A1
(en)
|
2018-05-10 |
2019-11-14 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
MA52590A
(fr)
|
2018-05-11 |
2021-03-17 |
Janssen Biotech Inc |
Méthodes de traitement de la dépression à l'aide d'anticorps il-23
|
TW202003048A
(zh)
|
2018-05-15 |
2020-01-16 |
美商伊繆諾金公司 |
用抗體-藥物偶聯物及flt3抑制劑之組合治療
|
EP3797173A2
(en)
|
2018-05-21 |
2021-03-31 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
AU2019272838A1
(en)
|
2018-05-23 |
2020-11-26 |
Adc Therapeutics Sa |
Molecular adjuvant
|
SG11202012706PA
(en)
|
2018-06-21 |
2021-01-28 |
Yumanity Therapeutics Inc |
Compositions and methods for the treatment and prevention of neurological disorders
|
MA52968A
(fr)
|
2018-06-23 |
2021-04-28 |
Hoffmann La Roche |
Méthodes de traitement du cancer du poumon à l'aide d'un antagoniste de liaison à l'axe pd-1, d'un agent de platine et d'un inhibiteur de la topoisomérase ii
|
US10976561B2
(en)
|
2018-06-29 |
2021-04-13 |
Viavi Solutions Inc. |
Optical devices with azimuthal modulator layer
|
WO2020003210A1
(en)
|
2018-06-29 |
2020-01-02 |
Kangwon National University University-Industry Cooperation Foundation |
Anti-l1cam antibodies and uses thereof
|
BR112021000673A2
(pt)
|
2018-07-18 |
2021-04-20 |
Genentech, Inc. |
métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
|
EP3824295A4
(en)
|
2018-07-18 |
2022-04-27 |
Janssen Biotech, Inc. |
PREDICTORS OF PROLONGED RESPONSE AFTER TREATMENT WITH AN ANTI-IL23 SPECIFIC ANTIBODY
|
CN112740043A
(zh)
|
2018-07-20 |
2021-04-30 |
皮埃尔法布雷医药公司 |
Vista受体
|
US20210186880A1
(en)
|
2018-08-03 |
2021-06-24 |
Brown University |
Oral formulations with increased uptake
|
TW202024023A
(zh)
|
2018-09-03 |
2020-07-01 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
WO2020061060A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
EP4249917A3
(en)
|
2018-09-21 |
2023-11-08 |
F. Hoffmann-La Roche AG |
Diagnostic methods for triple-negative breast cancer
|
CA3113837C
(en)
|
2018-09-24 |
2022-07-12 |
Janssen Biotech, Inc. |
Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
|
JP2022503959A
(ja)
|
2018-10-03 |
2022-01-12 |
ゼンコア インコーポレイテッド |
Il-12ヘテロ二量体fc-融合タンパク質
|
JP2022504287A
(ja)
|
2018-10-03 |
2022-01-13 |
スターテン・バイオテクノロジー・ベー・フェー |
ヒト及びカニクイザルapoc3に特異的な抗体、並びにその使用の方法
|
GB201816553D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
EP3863722A2
(en)
|
2018-10-10 |
2021-08-18 |
Tilos Theapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
GB201816554D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
CN113329769A
(zh)
|
2018-10-11 |
2021-08-31 |
斯克里普斯研究学院 |
具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物
|
KR20210079311A
(ko)
|
2018-10-18 |
2021-06-29 |
제넨테크, 인크. |
육종성 신장암에 대한 진단과 치료 방법
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
MX2021005905A
(es)
|
2018-11-20 |
2021-06-23 |
Janssen Biotech Inc |
Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
|
AU2019385497A1
(en)
|
2018-11-20 |
2021-06-17 |
Cornell University |
Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
|
US20220098310A1
(en)
|
2018-12-06 |
2022-03-31 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
US20220026445A1
(en)
|
2018-12-07 |
2022-01-27 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
EP3898679A2
(en)
|
2018-12-17 |
2021-10-27 |
Alligator Bioscience AB |
Polypeptides
|
WO2020127376A2
(en)
|
2018-12-17 |
2020-06-25 |
Alligator Bioscience Ab |
Novel polypeptides
|
US20200197517A1
(en)
|
2018-12-18 |
2020-06-25 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
|
CN113490666A
(zh)
|
2018-12-19 |
2021-10-08 |
奥瑞生物药品公司 |
作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
|
WO2020131674A1
(en)
|
2018-12-19 |
2020-06-25 |
Array Biopharma Inc. |
7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
|
CA3120476A1
(en)
|
2018-12-26 |
2020-07-02 |
Innate Pharma |
Leucocyte immunoglobulin-like receptor neutralizing antibodies
|
US20220017635A1
(en)
|
2018-12-28 |
2022-01-20 |
Kyowa Kirin Co., Ltd. |
BISPECIFIC ANTIBODY BINDING TO TfR
|
CA3126654A1
(en)
|
2019-01-15 |
2020-07-23 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
WO2020152544A1
(en)
|
2019-01-23 |
2020-07-30 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
|
JP2022519649A
(ja)
|
2019-02-08 |
2022-03-24 |
ジェネンテック, インコーポレイテッド |
がんの診断および治療方法
|
US11639388B2
(en)
|
2019-02-22 |
2023-05-02 |
Wuhan Yzy Biopharma Co., Ltd. |
CD3 antigen binding fragment and application thereof
|
WO2020176497A1
(en)
|
2019-02-26 |
2020-09-03 |
Rgenix, Inc. |
High-affinity anti-mertk antibodies and uses thereof
|
SG11202108707WA
(en)
|
2019-02-27 |
2021-09-29 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing t-cell function and predicting response to therapy
|
MX2021010313A
(es)
|
2019-02-27 |
2021-09-23 |
Genentech Inc |
Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
EA202192508A1
(ru)
|
2019-03-14 |
2022-03-29 |
Янссен Байотек, Инк. |
Способы получения композиций антитела к фно
|
JP2022525145A
(ja)
|
2019-03-14 |
2022-05-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12/il23抗体組成物を生成するための製造方法
|
MA55283A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de production de compositions d'anticorps anti-tnf
|
EP3938390A1
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
AU2020241428A1
(en)
|
2019-03-15 |
2021-08-12 |
Cartesian Therapeutics, Inc. |
Anti-BCMA chimeric antigen receptors
|
CN113853385A
(zh)
|
2019-03-18 |
2021-12-28 |
詹森生物科技公司 |
用抗il12/il23抗体治疗儿科受试者的银屑病的方法
|
JP2022527297A
(ja)
|
2019-03-27 |
2022-06-01 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Tn-MUC1キメラ抗原受容体(CAR)T細胞療法
|
CN113874392A
(zh)
|
2019-03-28 |
2021-12-31 |
丹尼斯科美国公司 |
工程化抗体
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
AU2020270376A1
(en)
|
2019-05-03 |
2021-10-07 |
Genentech, Inc. |
Methods of treating cancer with an anti-PD-L1 antibody
|
BR112021023295A2
(pt)
|
2019-05-23 |
2022-02-08 |
Janssen Biotech Inc |
Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
|
CA3142580A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
BR112021024425A2
(pt)
|
2019-06-03 |
2022-01-18 |
Janssen Biotech Inc |
Composições de anticorpo anti-tnf e métodos para o tratamento de artrite psoriática
|
CN114269749A
(zh)
|
2019-06-10 |
2022-04-01 |
苏特罗生物制药公司 |
5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
|
JP2022536800A
(ja)
|
2019-06-17 |
2022-08-18 |
ストロ バイオファーマ インコーポレーテッド |
Toll様受容体(tlr)7/8アゴニストとしての1-(4-(アミノメチル)ベンジル)-2-ブチル-2h-ピラゾロ[3,4-c]キノリン-4-アミン誘導体および関連化合物、ならびにがん療法および診断に使用するためのその抗体薬物コンジュゲート
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
AU2020335928A1
(en)
|
2019-08-30 |
2022-02-17 |
Agenus Inc. |
Anti-CD96 antibodies and methods of use thereof
|
WO2021043206A1
(zh)
|
2019-09-03 |
2021-03-11 |
百奥泰生物制药股份有限公司 |
一种抗tigit免疫抑制剂及应用
|
EP4025608A1
(en)
|
2019-09-04 |
2022-07-13 |
F. Hoffmann-La Roche AG |
Cd8 binding agents and uses thereof
|
JP2022549329A
(ja)
|
2019-09-26 |
2022-11-24 |
アムジェン インコーポレイテッド |
抗体組成物を製造する方法
|
JP2022549504A
(ja)
|
2019-09-26 |
2022-11-25 |
エスティーキューブ アンド カンパニー |
グリコシル化ctla-4に対して特異的な抗体およびその使用方法
|
WO2021062085A1
(en)
|
2019-09-27 |
2021-04-01 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021072277A1
(en)
|
2019-10-09 |
2021-04-15 |
Stcube & Co. |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
US20230024096A1
(en)
|
2019-10-29 |
2023-01-26 |
Hoffmann-La Roche Inc. |
Bifunctional compounds for the treatment of cancer
|
WO2021092171A1
(en)
|
2019-11-06 |
2021-05-14 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
WO2021097110A1
(en)
|
2019-11-13 |
2021-05-20 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
EP3825330A1
(en)
|
2019-11-19 |
2021-05-26 |
International-Drug-Development-Biotech |
Anti-cd117 antibodies and methods of use thereof
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
CN117417448A
(zh)
|
2019-12-13 |
2024-01-19 |
基因泰克公司 |
抗ly6g6d抗体及使用方法
|
WO2021127404A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
JP2023509760A
(ja)
|
2020-01-08 |
2023-03-09 |
シンシス セラピューティクス,インコーポレイテッド |
Alk5阻害剤複合体およびその使用
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
AU2021231890A1
(en)
|
2020-03-06 |
2022-09-29 |
Go Therapeutics, Inc. |
Anti-glyco-CD44 antibodies and their uses
|
KR20220151630A
(ko)
*
|
2020-03-06 |
2022-11-15 |
다이이찌 산쿄 가부시키가이샤 |
신규 고리형 디뉴클레오티드 유도체를 포함하는 항체 약물 컨쥬게이트
|
EP4118112A1
(en)
|
2020-03-10 |
2023-01-18 |
Massachusetts Institute of Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
WO2021197340A1
(zh)
|
2020-03-31 |
2021-10-07 |
百奥泰生物制药股份有限公司 |
用于治疗冠状病毒的抗体、融合蛋白及其应用
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
CA3175523A1
(en)
|
2020-04-13 |
2021-10-21 |
Antti Virtanen |
Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
|
CA3179891A1
(en)
|
2020-04-26 |
2021-11-04 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd |
Modified immunoglobulins
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
EP3915641A1
(en)
|
2020-05-27 |
2021-12-01 |
International-Drug-Development-Biotech |
Anti-cd5 antibodies and methods of use thereof
|
EP3915576A1
(en)
|
2020-05-28 |
2021-12-01 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Chimeric antigen receptors specific for p95her2 and uses thereof
|
EP4161653A1
(en)
|
2020-06-03 |
2023-04-12 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
EP4162257A1
(en)
|
2020-06-04 |
2023-04-12 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
AU2021293038A1
(en)
|
2020-06-16 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating triple-negative breast cancer
|
EP4168118A1
(en)
|
2020-06-18 |
2023-04-26 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
WO2022002873A1
(en)
|
2020-06-30 |
2022-01-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
|
US20230266322A1
(en)
|
2020-06-30 |
2023-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
|
EP3939999A1
(en)
|
2020-07-14 |
2022-01-19 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
|
CA3189336A1
(en)
|
2020-07-24 |
2022-01-27 |
Amgen Inc. |
Immunogens derived from sars-cov2 spike protein
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
EP4189121A1
(en)
|
2020-08-03 |
2023-06-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
KR20230042301A
(ko)
|
2020-08-04 |
2023-03-28 |
애벗트 라보라토리이즈 |
샘플에서 sars-cov-2 단백질을 검출하기 위한 개선된 방법 및 키트
|
TW202214698A
(zh)
|
2020-08-07 |
2022-04-16 |
大陸商百奧泰生物製藥股份有限公司 |
抗pd-l1抗體及其應用
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
EP4210832A1
(en)
|
2020-09-14 |
2023-07-19 |
Vor Biopharma, Inc. |
Chimeric antigen receptors for treatment of cancer
|
US20220119409A1
(en)
|
2020-09-23 |
2022-04-21 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
EP4225443A1
(en)
|
2020-10-05 |
2023-08-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
CA3197930A1
(en)
|
2020-10-15 |
2022-04-21 |
Amgen Inc. |
Relative unpaired glycans in antibody production methods
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
EP4242232A1
(en)
|
2020-11-06 |
2023-09-13 |
Bio-Thera Solutions, Ltd. |
Bispecific antibody and use thereof
|
WO2022103983A2
(en)
|
2020-11-11 |
2022-05-19 |
Sutro Biopharma, Inc. |
Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
|
EP4253415A1
(en)
|
2020-11-12 |
2023-10-04 |
Mabwell (Shanghai) Bioscience Co., Ltd. |
Antibody and preparation method therefor
|
WO2022104697A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Bliss Biopharmaceutical (Hangzhou) Co., Ltd. |
Modified egfr antibody with reduced affinity
|
US20220170948A1
(en)
|
2020-12-01 |
2022-06-02 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
JP2024503933A
(ja)
|
2021-01-27 |
2024-01-29 |
イノベント バイオロジクス(スーチョウ)カンパニー,リミティド |
Cd16aに対する単一ドメイン抗体およびその使用
|
TW202241454A
(zh)
|
2021-02-01 |
2022-11-01 |
日商第一三共股份有限公司 |
抗體-免疫賦活化劑共軛物之新穎製造方法
|
CR20230382A
(es)
|
2021-02-12 |
2023-09-06 |
Hoffmann La Roche |
Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
EP4301782A1
(en)
|
2021-03-05 |
2024-01-10 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
AU2022232375A1
(en)
|
2021-03-09 |
2023-09-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Cd3及びgpc3に結合するヘテロ二量体抗体
|
JP2024510588A
(ja)
|
2021-03-12 |
2024-03-08 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体による、tnf療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
|
BR112023018353A2
(pt)
|
2021-03-12 |
2024-02-06 |
Janssen Biotech Inc |
Método seguro e eficaz para tratamento da artrite psoriática com anticorpo específico anti-il23
|
WO2022191313A1
(ja)
|
2021-03-12 |
2022-09-15 |
第一三共株式会社 |
糖鎖及び糖鎖を含む医薬品の製造方法
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
JP2024517844A
(ja)
|
2021-05-04 |
2024-04-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
多重特異性fgf21受容体アゴニスト及びそれらの使用
|
US20220381796A1
(en)
|
2021-05-18 |
2022-12-01 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
EP4347603A1
(en)
|
2021-05-25 |
2024-04-10 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
CA3222409A1
(en)
|
2021-06-07 |
2022-12-15 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
US20240118279A1
(en)
|
2021-06-14 |
2024-04-11 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
JP2024522213A
(ja)
|
2021-06-14 |
2024-06-11 |
アルジェニクス ビーブイ |
抗il-9抗体及びその使用方法
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
IL309987A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-IL12/IL23 antibody compositions
|
IL309996A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-TNF antibody compositions
|
KR20240034218A
(ko)
|
2021-07-09 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물을 생산하기 위한 제조 방법
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
WO2023010118A1
(en)
|
2021-07-29 |
2023-02-02 |
Vor Biopharma Inc. |
Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
|
WO2023014863A1
(en)
|
2021-08-05 |
2023-02-09 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
EP4384522A1
(en)
|
2021-08-10 |
2024-06-19 |
Erasca, Inc. |
Selective kras inhibitors
|
EP4388008A1
(en)
|
2021-08-16 |
2024-06-26 |
Hemogenyx Pharmaceuticals Llc |
Anti-flt3 antibodies, cars, car t cells and methods of use
|
AU2022328625A1
(en)
|
2021-08-17 |
2024-03-21 |
Eli Lilly And Company |
Bispecific anti-flt3/cd3 antibodies and methods of use
|
AU2022339759A1
(en)
|
2021-08-31 |
2024-03-07 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
AU2022339667A1
(en)
|
2021-09-03 |
2024-04-11 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
CA3230933A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
WO2023051663A1
(zh)
|
2021-09-30 |
2023-04-06 |
百奥泰生物制药股份有限公司 |
抗b7-h3抗体及其应用
|
AU2022354059A1
(en)
|
2021-09-30 |
2024-03-28 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
AU2022361382A1
(en)
|
2021-10-05 |
2024-03-28 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
IL312401A
(en)
|
2021-10-29 |
2024-06-01 |
Janssen Biotech Inc |
Methods for treating Crohn's disease with a specific anti-IL23 antibody
|
WO2023079058A1
(en)
|
2021-11-05 |
2023-05-11 |
Yokogawa Insilico Biotechnology Gmbh |
Cell culture with reduced production of lactate
|
CA3238377A1
(en)
|
2021-11-15 |
2023-05-19 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
CA3239216A1
(en)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
WO2023097194A2
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
CA3240822A1
(en)
|
2021-12-17 |
2023-06-22 |
Tony Lee |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
AU2022424002A1
(en)
|
2021-12-29 |
2024-06-13 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023164487A1
(en)
|
2022-02-22 |
2023-08-31 |
Brown University |
Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
|
EP4245772A1
(en)
|
2022-03-18 |
2023-09-20 |
Netris Pharma |
Anti-netrin-1 antibody to treat liver inflammation
|
EP4249509A1
(en)
|
2022-03-22 |
2023-09-27 |
Netris Pharma |
Anti-netrin-1 antibody against arthritis-associated pain
|
WO2023186968A1
(en)
|
2022-03-29 |
2023-10-05 |
Netris Pharma |
Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
|
EP4253418A1
(en)
|
2022-03-29 |
2023-10-04 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
|
WO2023187707A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of treating mild to moderate psoriasis with il-23 specific antibody
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20230374122A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
US20240091365A1
(en)
|
2022-06-27 |
2024-03-21 |
Sutro Biopharma, Inc. |
Beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024015229A1
(en)
|
2022-07-15 |
2024-01-18 |
Sutro Biopharma, Inc. |
Protease/enzyme cleavable linker-payloads and protein conjugates
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
KR20240066490A
(ko)
|
2022-10-28 |
2024-05-16 |
주식회사 휴온스랩 |
항체-사이토카인 융합단백질 및 이의 용도
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|
US20240199734A1
(en)
|
2022-11-22 |
2024-06-20 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2024118866A1
(en)
|
2022-12-01 |
2024-06-06 |
Modernatx, Inc. |
Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
|